Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

McMaster University

$21,000.00

Altering fibrotic and rejection responses using biomaterial systems

EF 2013-14

Résumé
From the established (e.g. stitches) to the futuristic (e.g. tissue-engineered constructs), polymers have found diverse applications as implanted biomaterials. Yet, their utility is limited by the accumulation of fibrous tissue that inevitably occurs and accompanying immune responses. The long-term objective of the proposed research program is to design biomaterial systems that minimise fibrosis and allogeneic rejection. In order to accomplish these goals, we have two major aims within the five year duration of the grant. 1) Using a model biomaterial, we will deliver candidate anti-fibrotic drugs to decrease local scarring responses. 2) By delivering key compounds from the biomaterial, we will induce tolerogenic cells that reduce allogeneic rejection. Creation of biologically active ""combination"" devices is relatively recent and has been driven primarily by tissue engineering. However (and despite more complex regulatory issues), the field of implanted devices will also benefit greatly from biomaterials that actively direct responses away from fibrosis and rejection. The macrophage has been identified as the key cell activated by biomaterials. Recent research has shown that macrophages can differentiate into a spectrum of phenotypes that control subsequent wound-healing, scarring and immune responses. We hypothesize that controlled release of drugs from a biomaterial construct will direct these macrophages to regenerative, tolerogenic phenotypes. Thus, subsequent responses to a biomaterial scaffold would abrogate scarring and induce tolerance to allogeneic cells introduced as part of the tissue engineered construct. This engineering challenge is both scientifically and clinically significant. By moving beyond chemistry, we have the opportunity to rationally design biomaterial systems that actively interact with the recipient's inflammatory, fibrotic and immune responses. Moving to biologically active ""combination products"" will improve outcomes for traditional medical devices and for newer regenerative medicine applications.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
298472-2011
Name nom
Jones, Kim
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2011
Award amount
21000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
3
Nb partie
5
Application title
Altering fibrotic and rejection responses using biomaterial systems
Keyword
NSERC
Application summary
From the established (e.g. stitches) to the futuristic (e.g. tissue-engineered constructs), polymers have found diverse applications as implanted biomaterials. Yet, their utility is limited by the accumulation of fibrous tissue that inevitably occurs and accompanying immune responses. The long-term objective of the proposed research program is to design biomaterial systems that minimise fibrosis and allogeneic rejection. In order to accomplish these goals, we have two major aims within the five year duration of the grant. 1) Using a model biomaterial, we will deliver candidate anti-fibrotic drugs to decrease local scarring responses. 2) By delivering key compounds from the biomaterial, we will induce tolerogenic cells that reduce allogeneic rejection. Creation of biologically active ""combination"" devices is relatively recent and has been driven primarily by tissue engineering. However (and despite more complex regulatory issues), the field of implanted devices will also benefit greatly from biomaterials that actively direct responses away from fibrosis and rejection. The macrophage has been identified as the key cell activated by biomaterials. Recent research has shown that macrophages can differentiate into a spectrum of phenotypes that control subsequent wound-healing, scarring and immune responses. We hypothesize that controlled release of drugs from a biomaterial construct will direct these macrophages to regenerative, tolerogenic phenotypes. Thus, subsequent responses to a biomaterial scaffold would abrogate scarring and induce tolerance to allogeneic cells introduced as part of the tissue engineered construct. This engineering challenge is both scientifically and clinically significant. By moving beyond chemistry, we have the opportunity to rationally design biomaterial systems that actively interact with the recipient's inflammatory, fibrotic and immune responses. Moving to biologically active ""combination products"" will improve outcomes for traditional medical devices and for newer regenerative medicine applications.